Published in Proc Natl Acad Sci U S A on March 22, 2010
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer (2013) 1.22
Predicting response to epigenetic therapy. J Clin Invest (2014) 1.16
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol (2010) 1.03
Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol (2012) 0.98
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther (2014) 0.98
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther (2013) 0.92
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun (2015) 0.91
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2015) 0.89
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ (2013) 0.89
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. Sci Data (2014) 0.85
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Sci Rep (2014) 0.85
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics (2015) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther (2013) 0.83
Characterization of Dynamic UbR-Proteasome Subcomplexes by In vivo Cross-linking (X) Assisted Bimolecular Tandem Affinity Purification (XBAP) and Label-free Quantitation. Mol Cell Proteomics (2016) 0.83
A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. Cell Death Differ (2016) 0.80
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy. PLoS One (2014) 0.80
High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin. Oncotarget (2015) 0.78
Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol (2014) 0.78
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. J Pathol Clin Res (2016) 0.77
Vorinostat-An Overview. Indian J Dermatol (2015) 0.77
Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors. Comput Math Methods Med (2014) 0.77
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals (Basel) (2010) 0.76
Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clin Epigenetics (2010) 0.76
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. Br J Cancer (2016) 0.75
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J Natl Cancer Inst (2015) 0.75
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors. Oncotarget (2016) 0.75
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma. PLoS One (2017) 0.75
Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol (2017) 0.75
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Basic principles of ROC analysis. Semin Nucl Med (1978) 27.12
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J (2010) 3.90
Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol Cell Biol (2002) 3.01
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep (2001) 2.10
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs (2007) 1.95
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol (2005) 1.71
Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett (2009) 1.53
Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today (2006) 1.51
HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol (2009) 1.45
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis (2001) 1.40
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol (2008) 1.38
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett (2009) 1.31
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood (2009) 1.12
Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des (2007) 0.99
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy (2011) 3.47
Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat Protoc (2012) 3.30
Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax (2010) 3.30
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol (2003) 3.12
Arginine methylation regulates the p53 response. Nat Cell Biol (2008) 2.94
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol (2011) 2.28
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (2002) 2.26
Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood (2002) 2.20
Factors associated with severe illness in pandemic 2009 influenza a (H1N1) infection: implications for triage in primary and secondary care. J Infect (2011) 2.17
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol (2009) 1.96
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood (2010) 1.88
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
Folic Acid-conjugated Graphene Oxide loaded with Photosensitizers for Targeting Photodynamic Therapy. Theranostics (2011) 1.83
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res (2002) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys (2003) 1.73
The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) (2004) 1.72
The challenge of cancer control in Africa. Nat Rev Cancer (2008) 1.71
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol (2005) 1.71
Atypical E2F activity restrains APC/CCCS52A2 function obligatory for endocycle onset. Proc Natl Acad Sci U S A (2008) 1.70
E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene (2005) 1.69
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res (2002) 1.68
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2007) 1.66
Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.61
DNA-damage response control of E2F7 and E2F8. EMBO Rep (2008) 1.60
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood (2004) 1.60
Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood (2007) 1.59
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58
Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. Biomaterials (2011) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet (2007) 1.55
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol (2002) 1.54
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol (2002) 1.54
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 1.54
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol (2003) 1.54
Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol (2004) 1.53
Hypoxia and myocardial remodeling in human cardiac allografts: a time-course study. J Heart Lung Transplant (2009) 1.52
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today (2006) 1.51
Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials (2011) 1.50
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies. BMC Med Genomics (2012) 1.45
Arginine methylation controls growth regulation by E2F-1. EMBO J (2012) 1.44
E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene (2004) 1.44
Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med (2008) 1.42
Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst (2003) 1.42
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
The yin and yang of E2F-1: balancing life and death. Nat Cell Biol (2003) 1.40
Mycosis fungoides with tinea pseudoimbricata owing to Trichophyton rubrum infection. J Cutan Med Surg (2007) 1.39
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res (2012) 1.39
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol (2008) 1.38
Cutaneous manifestations of Hodgkin's disease. Int J Dermatol (2006) 1.36
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med (2013) 1.36
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol (2010) 1.34
Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep (2006) 1.33
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res (2004) 1.33
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol (2006) 1.31
Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett (2009) 1.31
Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res (2003) 1.29
Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol (2004) 1.29
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol (2010) 1.29
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought. J Clin Oncol (2013) 1.26
Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J (2010) 1.25
Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res (2005) 1.25
Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax (2006) 1.24
Skin cancer detection by spectroscopic oblique-incidence reflectometry: classification and physiological origins. Appl Opt (2004) 1.22
A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. Prenat Diagn (2013) 1.22
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat (2008) 1.22
The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun (2005) 1.22
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol (2010) 1.20
Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res (2008) 1.19